POEMs: Patient-Oriented Evidence that Matters

POEMs (Patient-Oriented Evidence that Matters) are summaries of research that is relevant to physicians and their patients and meet three criteria: address a question that primary care physicians face in day-to-day practice; measure outcomes important to physicians and patients, including symptoms, morbidity, quality of life, and mortality; and have the potential to change the way physicians practice.

Oct 01, 2021 Issue
High-Dose Amoxicillin/Clavulanate No Better than Standard Dose for Acute Sinusitis in Adults
This study found no significant difference between the standard-dose and high-dose regimens of amoxicillin/clavulanate for treating acute sinusitis in adults. It is important to note that both doses are minimally superior to placebo.

Oct 01, 2021 Issue
For Patients with Type 2 Diabetes Mellitus Who Are Taking a GLP-1 Receptor Agonist, an SGLT2 Inhibitor May Be Preferred to a Sulfonylurea as Add-on Therapy
This propensity score–matched analysis (not funded by industry) concluded that an SGLT2 inhibitor is preferred over a sulfonylurea for patients with type 2 diabetes who are already taking a GLP-1 receptor agonist, with favorable effects on the likelihood of hospitalization for myocardial infarction and heart failure, and all-cause mortality.

Oct 01, 2021 Issue
No Difference in Cognitive Decline in Older Patients with Coronary Artery Disease Undergoing CABG or PCI
The study found no significant difference in the rate of memory decline among older adults with CAD who are undergoing coronary revascularization with CABG or PCI.

Oct 01, 2021 Issue
Screening for Ovarian Cancer with CA 125 and Ultrasound Algorithm Does Not Reduce Mortality
Like the U.S. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, this large and long U.K. study found no reduction in ovarian cancer mortality with screening using ultrasonography or a multimodal CA 125–based screening strategy.

Sep 01, 2021 Issue
Take-and-Hold Prescriptions for Children with Respiratory Tract Infections Decrease Antibiotic Use with Similar Outcomes
A strategy of providing education about the natural history of respiratory symptoms in children combined with giving a take-and-hold prescription (to be filled only if symptoms persisted) resulted in one in four of those children eventually receiving an antibiotic.

Sep 01, 2021 Issue
In Older Adults, Aspirin Increases the Risk of Metastatic or Stage 4 Cancers and Cancer Mortality
In this large trial, older adults who received aspirin had higher rates of metastatic cancer, stage 4 cancer, and cancer mortality than those who received placebo.

Sep 01, 2021 Issue
Epidural Corticosteroid Injections Provide Minimal, If Any, Benefit in Low Back Pain with Sciatica
Epidural corticosteroid injections provide a small and probably clinically insignificant reduction in leg and back pain in the immediate term (less than two weeks), and a small to moderate reduction in disability in the short and intermediate terms.

Sep 01, 2021 Issue
The Risk of Progression from Prediabetes to Diabetes in Older Adults Is Low
Older patients generally will not progress to diabetes; they will either, over an average of 6.5 years, stay at the prediabetic levels or revert to normal levels. If a patient makes it to their mid-70s without a diagnosis of diabetes, it is unlikely to occur.

Aug 01, 2021 Issue
Inhaled Budesonide Reduces the Risk of Emergency Department Evaluation or Hospitalization in Early COVID-19
Inhaled budesonide, 800 mcg twice daily, significantly reduces the likelihood that patients with early COVID-19 will require emergency department evaluation or hospitalization (number needed to treat = 7 to 8). This is a widely available, relatively inexpensive drug with the potential for great benefit.

Aug 01, 2021 Issue
SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes
SGLT2 inhibitors, the diabetes medications ending in -flozin, and GLP-1 receptor agonists, the -tide medications, decrease cardiovascular and renal outcomes to a greater extent than placebo or other treatments. They should be considered in addition to metformin and other glucose-lowering treatments for most patients with type 2 diabetes.

Pages: 1 2 3 4 5 6 7 8 9 10 ... 42 Next

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now